Ribosomal Protein S6 Kinases
"Ribosomal Protein S6 Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of protein serine/threonine kinases which act as intracellular signalling intermediates. Ribosomal protein S6 kinases are activated through phosphorylation in response to a variety of HORMONES and INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS. Phosphorylation of RIBOSOMAL PROTEIN S6 by enzymes in this class results in increased expression of 5' top MRNAs. Although specific for RIBOSOMAL PROTEIN S6 members of this class of kinases can act on a number of substrates within the cell. The immunosuppressant SIROLIMUS inhibits the activation of ribosomal protein S6 kinases.
| Descriptor ID |
D019893
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.862 D12.644.360.600 D12.776.476.600
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ribosomal Protein S6 Kinases".
Below are MeSH descriptors whose meaning is more specific than "Ribosomal Protein S6 Kinases".
This graph shows the total number of publications written about "Ribosomal Protein S6 Kinases" by people in this website by year, and whether "Ribosomal Protein S6 Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ribosomal Protein S6 Kinases" by people in Profiles.
-
Zhao L, Wang Y, Sun X, Zhang X, Simone N, He J. ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer. Int J Mol Sci. 2024 Feb 17; 25(4).
-
Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018 05; 8(5):568-581.
-
Yarchoan M, Ma C, Troxel AB, Stopenski SJ, Tang W, Cohen AB, Pappas-Paxinos M, Johnson BA, Chen EY, Feldman MD, Brose MS. pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer. Horm Cancer. 2016 06; 7(3):188-95.
-
Andreoni KA, Wang X, Huang SM, Huang ES. Human cytomegalovirus hyperimmune globulin not only neutralizes HCMV infectivity, but also inhibits HCMV-induced intracellular NF-kappaB, Sp1, and PI3-K signaling pathways. J Med Virol. 2002 May; 67(1):33-40.